FDA Calendar for Cephalon, Inc. (CEPH)

| Register (free)
Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and commercialization of products in four core therapeutic areas: central nervous system (CNS), pain, oncology and inflammatory disease. In addition to conducting an active research and development program, it markets seven products in the United States and numerous products in various countries throughout Europe and the world. Its principal product are its wakefulness products, PROVIGIL (modafinil) Tablets [C-IV] and NUVIGIL (armodafinil) Tablets [C-IV], which comprised 51% of its total consolidated net sales during the year ended December 31, 2009. During 2009, Cephalon, Inc. acquired an exclusive, worldwide license to the ImmuPharma investigational compound, LUPUZOR, which is in Phase IIb development for the treatment of systemic lupus erythematosus. In August 2009, Cephalon, Inc. completed the acquisition of Arana Therapeutics Limited.

Around The Net


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Nuvigil Other Pending DecisionNDA


Events

No future events listed at this time, please check back later.
1 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

$0.00
0
1/1/0001 12:00:00 AM

Sponsors

Other Links